More Videos
- Getting to the Heart of the Merck-Abbott Embargo Break
- Merck: Both Sides Now
- A Public Hearing That Isn't Public
- Fighting The Flu Vaccine Critics
- Merck’s Mega-Monday Morning
- What Not To Wear At Sanofi-Pasteur
- Merck: Live Long And Prosper
- Lights, Camera, Lipitor!
- Biopharma's Bustin' Out All Over
- Friday At The Fat Fight
SPECIAL REPORT
MOST SHARED
- Stocks Overvalued, Recession Will Return: Meredith Whitney
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- Warren Buffett's Berkshire Hathaway Almost Doubles Wal-Mart Holdings During Summer
- U.S. May Wind Up Green With Envy
- BofA Ex-Counsel: I Was 'Stunned' When I Got Fired
- Time Warner to Spin Off AOL on December 9
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- Solar Emerges From A Dark Period
- Stocks May Rise Further after Fed Waves on 'Risk Trade'
- Millions May Have to Repay Part of Obama Tax Credit
- Answers to Your Questions: A Path to Economic Disaster?
- 5 Ways to Play the Chinese Markets: Analyst
- Meredith Whitney: Turns Bearish
- 3 Stock Plays on Rising College Costs
- Warren Buffett's Berkshire Hathaway Almost Doubles Wal-Mart Holdings During Summer
- Nov. 16: Unusual Volume Leaders
- Getting to the Heart of the Merck-Abbott Embargo Break
- What MGM's Sale Could Say About Value of Content
- My Ratings on Lowe's & Home Depot: Analyst
- Stocks May Rise Further after Fed Waves on 'Risk Trade'
- Obama in China Grapples with Economic Strains
- Buffett's Berkshire Hathaway Boosts Stake in Wal-Mart
- Microsoft Co-founder Allen Diagnosed with Cancer
- Time Warner to Spin Off AOL on December 9
- Gates Boosts Waste Management, Coca Cola Stakes
- What's Kept Stock Rally Going? Fear, Not Confidence
- US Cities With Most Underwater Mortgages
- Citi Shares, A Strange Indicator Of Unemployment?
PHARMA'S MARKET VIDEO
Cholesterol Drug Battle: Niaspan vs. Zetia 
16 Nov 2009Cardiologist Grades Cholesterol Drug Study 16 Nov 2009
Merck's Cholesterol Drugs Under Pressure 16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs 16 Nov 2009
Cholesterol Drug Battle 16 Nov 2009
Novo Nordisk CEO on Diabetes Epidemic 13 Nov 2009
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com American Diabetes Association |
We are covering the ADA meeting today and tomorrow because most of the major data came out over the weekend or is coming out later today. Or so we thought.
Novo Nordisk [NVO
Loading...
()
] surprised the market with a press release saying its late-stage developmental drug is better than a similar one already on the market--Byetta from Eli Lilly [LLY
Loading...
()
] and Amylin Pharmaceuticals [AMLN
Loading...
()
] .
The market downdraft was huge Friday, but AMLN shares plummeted around nine percent. NVO rallied two percent.
Byetta is a twice-a-day injectable. Novo's drug, liraglutide, is a one-a-day.
A Novo spokesman says the Danish company was burning the midnight oil trying to get the data cleaned in time to possibly get out a press release at ADA.
A competitor and at least one critic are calling out Novo since it's a press release and the data were not peer-reviewed for official presentation here at ADA. In other words, companies that want to unveil data at a prestigious scientific conference like this one have to get their studies to pass muster first with experts who decide which studies get in and how they'll be presented. There are different tiers of presentation methods, venues and forums at these things. It's a big deal.
The Novo spokesman says the company had a regulatory and fiduciary responsibility to get out the test results as soon as they were ready.
In a scathing note to subscribers David Kliff who writes a newsletter called "Diabetic Investor" says, "With their bush league tactics Novo was deliberately trying to control the news flow, damage Amylin’s share price and steal Amylin’s thunder." Kliff is a longtime AMLN/Byetta bull. He says he does not own any stocks of the companies he covers.
Amylin's thunder could be made at 9 pm ET tonight when it will release major longer-term test results on a once-a-week version of Byetta. At a meeting with analysts and investors here last night I'm told Amylin officials did not move up their timeline for filing for FDA approval of once-a-week Byetta. They're still saying it'll be by the end of the first half of next year. Some analysts were speculating LLY and AMLN would use the ADA venue to announce they're speeding things up.
These drugs called GLP-1s are being widely followed by investors because they not only help diabetics lower their blood sugar, but also lose weight. Many analysts expect the class (Roche is working on one, too) to become a multi-billion-dollar piece of the exploding diabetes market.
Amylin's CEO Dan Bradbury will be live with me for a First on CNBC interview tomorrow morning on "Squawk on the Street" between 9 and 11 am ET.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes